AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
AbCellera (Nasdaq: ABCL) presented new data on its T-cell engager (TCE) platform at the SITC 37th Annual Meeting, highlighting a diverse panel of CD3-binding antibodies for potential cancer treatments. The research includes proof-of-concept studies demonstrating T-cell engagers that effectively kill cancer cells while minimizing cytokine release. The company aims to enhance the development of bispecific antibodies, addressing the challenges of T-cell activation and specificity. AbCellera's advancements underscore its rapid antibody discovery capabilities and potential market impact.
- Presentation of a diverse panel of CD3-binding antibodies enhances potential for T-cell engagers in cancer treatment.
- Proof-of-concept study shows T-cell engagers potently kill cancer cells with low cytokine release, reducing toxicity risks.
- Rapid expansion of data supporting T-cell engager platform showcases the efficiency of AbCellera's antibody discovery engine.
- None.
- Expanded characterization of CD3-binding antibodies includes identification of antibodies that bind regions of CD3 that are distinct from commonly used molecules
- Robust proof-of-concept study demonstrates T-cell engagers that potently eliminate cancer cells with minimal cytokine release
“The robust data package we are presenting at SITC demonstrates that our panel includes antibodies that are distinct from molecules commonly used for CD3 T-cell engager development,” said
CD3 T-cell engagers are bispecific antibodies that redirect T cells to kill tumor cells. Developing effective T-cell engagers requires two parental antibodies: a CD3-binding arm that fine-tunes T-cell activation and a tumor-binding arm with high specificity for cancer cells. Pairs of parental antibodies that work well together are rare, creating a need for diverse panels of developable antibodies that can be combined and tested at scale to find optimal clinical candidates.
To address the paucity of anti-CD3 antibodies for TCEs, AbCellera used its integrated antibody discovery, characterization, and engineering technologies to discover and validate an extensive panel of fully human CD3-binding antibodies. New data presented at SITC includes epitope binning analysis, revealing antibodies with species cross-reactivity that bind epitopes distinct from commonly used parental antibodies, such as SP34-2. AbCellera also conducted a second discovery campaign strategically designed to enhance the number of cross-reactive antibodies in the panel, resulting in hundreds of additional unique antibody sequences to be characterized.
Developing bispecific antibodies that potently eliminate cancer cells without inducing toxicity has been a significant challenge limiting T-cell engager development. In a proof-of-concept study, AbCellera used its OrthoMabTM bispecifics platform to create CD3 x EGFR T-cell engagers. High-throughput functional and biophysical assays identified potent tumor-cell killing T-cell engager molecules that maintained low levels of cytokine production without the need for further engineering or optimization.
“We debuted our T-cell engager platform at the AACR annual meeting in April of this year, and in less than six months, we have greatly expanded the data package supporting this platform,” said
Details on AbCellera’s presentation at SITC are as follows:
Title: Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine
Poster Number: 1196
Date and Time:
Location:
The poster is available for viewing here.
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005958/en/
Inquiries
Media:
Business Development:
Investor Relations:
Source:
FAQ
What new data did AbCellera present at the SITC 2022 meeting?
How do the new CD3-binding antibodies improve T-cell engager development by AbCellera?
What was demonstrated in the proof-of-concept study by AbCellera's T-cell engagers?
When was AbCellera's presentation at the SITC 2022 scheduled?
What is the significance of the T-cell engager platform for AbCellera?
